Does the Negativation of the Glucose Hydrogen Breath Test Come Along With a Reduction of the Symptoms of Gaz Incontinence ?
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Rouen, France, 76031
- Physiology Unit, Hopital Charles Nicolle, 1 rue de Germont
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Gaz incontinence for more than 3 months
- Afflilied to national health security
- Having read and sign the information letter and consent form
Exclusion Criteria:
- Pregnancy
- use of antibiotics, probiotics, IPP for less tha n 3 months
- past of small intestinal bacterial overgrowth
- ischemic, inflammatory colitis,colo-rectal cancer
- diabetes
- allergy to metronidazole
- psychiatric disease
- patients who do not speak or read french
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Metronidazole
3 intakes per day during 10 days
|
Metronidazole,per os,500mg, 3 per day during 10 days
|
|
Active Comparator: Carbosylane
3 intakes per daysduring 10 days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
number of gaz incontinence episodes
Time Frame: 3 days before randomization and treatement and 3 days after 10 days of treatment (antibiotic or conventionnal treatment
|
3 days before randomization and treatement and 3 days after 10 days of treatment (antibiotic or conventionnal treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Signs and Symptoms, Digestive
- Behavioral Symptoms
- Elimination Disorders
- Pathological Conditions, Signs and Symptoms
- Behavior
- Signs and Symptoms
- Encopresis
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Azoles
- Imidazoles
- Nitroimidazoles
- Nitro Compounds
- Metronidazole
Other Study ID Numbers
Other Study ID Numbers
- 2008/073/HP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.